Clostridium difficile-associated disease: an emerging threat to patient safety: insights from the Society of Infectious Diseases Pharmacists.
about
WSES guidelines for management of Clostridium difficile infection in surgical patientsPro/con debate: Should antimicrobial stewardship programs be adopted universally in the intensive care unit?Clostridium difficile Infection and Inflammatory Bowel Disease: A Review.Identification of toxemia in patients with Clostridium difficile infection.Loss of Microbiota-Mediated Colonization Resistance to Clostridium difficile Infection With Oral Vancomycin Compared With MetronidazoleEmerging therapies in the treatment of Clostridium difficile-associated disease.Nutrition support and the chronic critical illness syndrome.An overview of harms associated with beta-lactam antimicrobials: where do the carbapenems fit in?Past, present, and future therapies for Clostridium difficile-associated disease.Antimicrobial-associated risk factors for Clostridium difficile infection.Skin and skin structure infections: treatment with newer generation fluoroquinolones.Insights from the Society of Infectious Diseases Pharmacists on antimicrobial stewardship guidelines from the Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America.Clostridium difficile Outbreak: A Small Group of Pharmacists Makes a Big Impact.Non-steroidal anti-inflammatory drugs and the risk of Clostridium difficile-associated disease.Severe pseudomembranous colitis after moxifloxacin use: a case series.Treatment of Clostridium difficile infection in a French university hospital.Measures to control and prevent Clostridium difficile infection.Treatment of Clostridium difficile infection.
P2860
Q26795429-73303372-FCEA-455C-AAD0-428792D052CCQ33873338-1E45E8CC-8B84-44EA-A8A9-C2D3136686A5Q35208564-A68B82E9-1B62-4067-AE98-6C7EDCDBA43AQ35465119-2741AB5F-D48F-47EE-9A50-F713E3F9D3ABQ36208584-FB10F28E-8CDC-4235-94E1-9A13A79CBA9EQ36659957-FCBB81A5-9F1B-47F0-8041-CEC01EFDC1B3Q36659996-D2613F1C-1E83-4365-B8E5-98F6D953FAC0Q36667925-AD12E3E0-8212-4CED-A217-47ABA29BD1BEQ36674768-A0F8F713-84F0-44C1-978B-1898B1028BD4Q37051298-F81E9DE4-AC2C-428C-86AC-18D981B21FD8Q37116838-B908AD88-ADBB-405A-AABD-11575ABE2790Q37461442-444D5D65-3C65-4D0F-89A6-E4EC204555CBQ39211873-E51C3403-3462-44D6-9477-C706875A4212Q39956379-A8F47744-462D-4887-B142-05CABFC0A3B0Q40402747-C7DF0AD1-E1EE-4779-8976-4E939FB5315BQ41068418-573EF328-EDE7-4EC8-A7C1-5E6F2D9C14F8Q46821792-F5934B49-1FE0-4686-89BA-15AB6FF09A5FQ51894323-EE966083-B524-42D0-A08E-9F2DC8665586
P2860
Clostridium difficile-associated disease: an emerging threat to patient safety: insights from the Society of Infectious Diseases Pharmacists.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh
2006年學術文章
@zh-hant
name
Clostridium difficile-associat ...... fectious Diseases Pharmacists.
@ast
Clostridium difficile-associat ...... fectious Diseases Pharmacists.
@en
type
label
Clostridium difficile-associat ...... fectious Diseases Pharmacists.
@ast
Clostridium difficile-associat ...... fectious Diseases Pharmacists.
@en
prefLabel
Clostridium difficile-associat ...... fectious Diseases Pharmacists.
@ast
Clostridium difficile-associat ...... fectious Diseases Pharmacists.
@en
P2860
P356
P1433
P1476
Clostridium difficile-associat ...... fectious Diseases Pharmacists.
@en
P2093
Robert C Owens
P2860
P304
P356
10.1592/PHCO.26.3.299
P407
P577
2006-03-01T00:00:00Z